Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, according to a study presented at CHEST 2024 , the annual meeting of the American College of Chest Physicians, held from Oct. 6 to 9 in Boston. Surya P.
Bhatt, M.D., from the University of Alabama at Birmingham, and colleagues pooled data from two phase 3 trials evaluating the efficacy and safety of subcutaneous add-on dupilumab 300 mg or placebo every two weeks in 1,660 patients with COPD and type 2 inflammation (screening blood eosinophils ≥300 cells/μL), with moderate-to-severe airflow limitation, who were on triple therapy.
The researchers report that mean symptom domain scores were 59.3 for dupilumab versus 58.6 for placebo, mean activity scores were 66.
3 versus 65.8, and mean impact domain scores were 38.2 versus 37.
3. The least-squares mean difference at week 52 versus placebo was −3.366.
For individual St. George's Respiratory Questionnaire (SGRQ) domain mean scores, similar improvements were seen at week 52 (mean symptom domain score least-squares mean difference for the change from baseline to week 52 versus placebo, −3.502; mean activity domain score, −3.
997; mean impact domain score, −2.870). "Impairment in HRQoL is a significant contributor to morbidity in COPD," the authors write.
"These data demonstrate that dupilumab improves HRQoL, as measured by the SGRQ, in patients with COPD and type 2 inflammation." Se.